Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 16/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770288 | 1.00 | CREBBP (1.00) | CREBBPALKKLKB1L3MBTL1MET | |
| SCHEMBL20532189 | 0.82 | CREBBP (1.00) | CREBBPL3MBTL1 | |
| SCHEMBL20532295 | 0.77 | CREBBP (1.00) | CREBBP | |
| SCHEMBL20532419 | 0.76 | CREBBP (0.69) | CREBBP | |
| SCHEMBL18232748 | 0.76 | CREBBP (0.60) | CREBBPALKKLKB1 | |
| SCHEMBL20532278 | 0.75 | CREBBP (1.00) | CREBBPALKL3MBTL1 | |
| SCHEMBL20532073 | 0.75 | CREBBP (1.00) | CREBBP | |
| SCHEMBL30770310 | 0.75 | CREBBP (1.00) | CREBBP | |
| SCHEMBL19116683 | 0.74 | CREBBP (0.59) | CREBBPALKKLKB1L3MBTL1 | |
| SCHEMBL3918666 | 0.74 | GRM5 (0.62) | CREBBPALKL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293381-A1 | Therapeutic Compounds | CELGENE QUANTICEL RES INC (US) | 2024-09-05 | — | — | US | claimed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | claimed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | claimed |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2018-10-18 | — | — | US | claimed |
| US-20240293381-A1 | Therapeutic Compounds | CELGENE QUANTICEL RES INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-11890275-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. | 2024-02-06 | — | — | US | disclosed |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020380-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | CREBBP 18/4885ALK 2680/4885KLKB1 4268/4885 |
| US-20240293381-A1 | Therapeutic Compounds | EP300, BRD4, BRD3 | CREBBP 18/4885ALK 2680/4885KLKB1 4268/4885 |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | CREBBP 18/4885ALK 2680/4885KLKB1 4268/4885 |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | CREBBP 18/4885ALK 2680/4885KLKB1 4268/4885 |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | CREBBP 18/4885ALK 2680/4885KLKB1 4268/4885 |
| US-10617680-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | CREBBP 18/4885ALK 2680/4885KLKB1 4268/4885 |
| US-11890275-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | CREBBP 18/4885ALK 2680/4885KLKB1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.